Biotech Company of the Year
award recognizes a Canadian biotech company that has distinguished
itself from its peers with strong overall performance as a company,
demonstrated leadership and shown significant achievement. It will have
reached milestones in terms of financing, product introduction, and /
or partnerships during the year that has allowed the company to be
recognized as a leader. The company will have established a solid
foundation for a strong and diverse pipeline, and impressive potential
for sales and earnings. This award is based on performance in the
previous calendar year (2012).
Xenon Pharmaceuticals Inc. - 2013 Company of the Year Award
Xenon is a privately held biotechnology company that uses its human genetics platform to develop novel pharmaceuticals for rare diseases. Xenon licensed out one of its first technologies for the gene therapy treatment of a rare lipid disorder known as Lipoprotein Lipase Deficiency. The product, Glybera, was approved in Europe in 2012 and represents the first gene therapy product approved in Europe.
In 2012, Xenon entered into two major pharmaceutical deals for the treatment of pain. The first deal was a $646M partnership with Genentech. The second deal was a $376M partnership with Teva Pharmaceuticals. Xenon has raised almost $90M in non- dilutive R&D funding from alliance partners in the past 5 years in a challenging Canadian financing environment.
In addition to Glybera, Xenon’s pipeline includes two phase 2b products for treating pain partnered with Teva and a development stage product for treating anemia of chronic disease (expected to start clinical trials in 2013). Xenon’s pipeline is rounded out by additional exciting discovery stage assets which should form the basis of its future clinical products.
With a very strong balance sheet, a rich development and discovery pipeline and multiple top tier pharmaceutical partners, Xenon is poised for an exciting future.
Simon Pimstone, President of Xenon Pharma with the award for COMPANY OF THE YEAR
2004 - 2012 Past Award Recipients2012 - Enobia
2011 - Cardiome Pharma (see profile)
2010 - OncoGenex Technologies Inc. (see profile)
2009 - Arius Research Inc. (see profile)
2008 - BioMS Medical Corp
2007 - Theratechnologies Inc.,
2006 - Aspreva Pharmaceuticals
2005 - SemBioSys Genetics Inc.
2004 - Angiotech Pharmaceuticals, Inc.
2013 Biotech Company of the Year Nominees
Akshaya BIO Inc.
Island Abbey Foods Ltd.
Vertex Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.